Chugai gains marketing rights for Helsinn's palonosetron and NEPA for chemo nausea

17 July 2014

Japanese drugmaker Chugai (TYO: 4519), which is majority-owned by Swiss drug major Roche (ROG: SIX), has gained marketing rights to palonosetron in the UK and NEPA in the UK and Ireland from privately-held Swiss cancer specialists Helsinn Group.

The two companies are partnering on NEPA, an investigational oral fixed-dose combination of netupitant and palonosetron being evaluated for the prevention of chemotherapy-induced nausea and vomiting. Chugai has additionally been granted exclusive rights to market the palonosetron monotherapy, Aloxi (palonosetron HCI), in the UK from January next year.

NEPA is currently in the registration phase in the USA and Europe, and one of its components is palonosetron, the market-leading treatment for chemotherapy-induced nausea and vomiting. Palonosetron achieved worldwide sales in the region of $625 million in 2013, and is available in over 65 countries worldwide under the brand names of Aloxi, Onicit and Paloxi.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK